Dr. Troendle is the President and CEO of Medpace since it's inception in 1992. He previously worked for Sandoz (Novartis) where he was responsible for the clinical development of lipid altering agents. His past experience as Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA give him insight into the regulatory environment for development of drugs in the metabolic and cardiovascular fields. Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine.